您当前所在的位置:首页 > 产品中心 > 产品信息
Halobetasol Propionate_分子结构_CAS_66852-54-8)
点击图片或这里关闭

Halobetasol Propionate

产品号 DB00596 公司名称 DrugBank
CAS号 66852-54-8 公司网站 http://www.ualberta.ca/
分子式 C25H31ClF2O5 电 话 (780) 492-3111
分子量 484.9604464 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 478

产品价格信息

请登录

产品别名

标题
Halobetasol Propionate
IUPAC标准名
(1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate
IUPAC传统名
halobetasol propionate
商标名
Ultravate
Ulobetasol Propionate
Halobetasol

产品登记号

PubChem CID 48175
CAS号 66852-54-8
PubChem SID 46506187

产品性质

疏水性(logP) 2.9
溶解度 Mostly insoluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. It is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Indication For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Affected Organisms
Humans and other mammals
Absorption The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
External Links
RxList
PDRhealth
Drugs.com

参考文献